[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","wnlez0oo8a62zzv7i1b4elkg7","revision",2,"title","Ascentage Pharma 公布 2022 RSU 计划股份购买公告","originalTitle","6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)","summary","Ascentage Pharma 公布 2022 RSU 计划股份购买公告。公告显示信托人于 2026 年 10 月 15 日购买股份。该公告作为 6-K 报告附件 99.1 提交。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-15T13:26:31.000Z","discoveredAt","2026-10-15T15:39:50.772Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",21,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fAsutW-MmVhs",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","c86c09e6-70fd-49b2-b44e-e8f4cc01a66e","Ascentage Pharma 2022 RSU 计划股份购买",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,\nD.C. 20549

Form\n6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2026

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into\nEnglish)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual\nreports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form\n40-F ☐

On October 15, 2026, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) posted an announcement\non the Hong Kong Stock Exchange entitled, “PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME” . A copy\nof the announcement is furnished as Exhibit 99.1 to this Report.

INDEX TO EXHIBITS

\n \n \n \n \n \n \n \n \n

Exhibit Number		Exhibit Title
99.1		RSU Purchase Announcement dated October 15, 2026

SIGNATURE

Pursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto\nduly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	ASCENTAGE PHARMA GROUP INTERNATIONAL

Date: October 15, 2026	/s/ Dajun Yang
	Name: Dajun Yang
	Title: Chief Executive Officer

","zhKind","complete","AAPG","政策与监管","退市","停复牌","aihot","/items/wnlez0oo8a62zzv7i1b4elkg7","https://www.sec.gov/Archives/edgar/data/2023311/000121390026109623/0001213900-26-109623-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]